The Digital Therapeutics Market for software-based medical interventions intended to treat, manage, and prevent different diseases and health conditions is referred to as the “digital therapeutics market.” These solutions offer patients individualised care and support using digital technologies like wearables, mobile apps, and telemedicine. Due to the growing trend of digital health and the expanding adoption of technology in the healthcare industry, the demand for digital therapeutics has significantly increased in recent years. A growing number of factors, including the prevalence of chronic diseases, the ageing population, and the demand for affordable and practical healthcare solutions, are driving the market.
Based on application, end-user, and geography, the digital therapeutics market is divided into subgroups. According to application, the market can be divided into categories such as mental health, musculoskeletal disorders, cardiovascular diseases, and disorders of the central nervous system. The market can be divided into patients, healthcare providers, and payers based on end-user. The market can be divided geographically into four regions: North America, Europe, Asia-Pacific, and the rest of the world.
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=6314
Key Segments Covered in the Digital Therapeutics Industry Survey
- By Application Type
- Digital Therapeutics for Diabetes
- Digital Therapeutics for Obesity
- Digital Therapeutics for CVD
- Digital Therapeutics for Respiratory Diseases
- Digital Therapeutics for Smoking Cessation
- Digital Therapeutics for CNS Diseases
- By End User
- Digital Therapeutics for Patients
- Digital Therapeutics for Providers
- Digital Therapeutics for Payers
- Digital Therapeutics for Employers
Key Takeaways from the Market Study
- Globally, the digital therapeutics market is estimated to be worth US$ 5.27 Bn by 2022
- North America will hold a prominent position with 42% of global revenue by 2022
- Asia Pacific to flourish at a CAGR of 20% in the digital therapeutics domain until 2032
- By treatment, digital therapeutics for diabetes to comprise 28% of global market revenue
- Treatment for obesity to experience nearly 2x growth from 2022 to 2032
- The patient end-user segment will account for 32.5% of global revenue in 2022
Key Companies Profiled
- Omada Health Inc.
- WellDoc, Inc.
- 2Morrow, Inc.
- Livongo Health, Inc. (Teladoc Health Inc.)
- Propeller Health
- Fitbit Inc.
- Canary Health
- Mango Health
- Noom, Inc.
- Pear Therapeutics
- Dexcom
- Voluntis
Competitive Landscape
The market is dominated by several key players, who focus on innovative strategies for increasing revenues, such as mergers and acquisitions, market penetration, partnerships, and distribution agreements.
- For instance, The Teladoc Company strengthened their alliance with the National Labor Alliance in December 2021. Specialty care, general medicine, professional medical services, mental health, virtual primary care programs, and chronic illness management were some of the goods and services provided.
- Dexcom and Welldoc created an extensive, integrated platform in 2021 that improves the quality of life for people with type 2 diabetes. BlueStar assists persons with diabetes in managing the challenging process by employing the Dexcom G6 technology to test glucose levels under the skin.
- A digital therapeutic platform developed by Voluntis using its Theraxium platform to allow intelligent medication dosage for diabetes titration has a patent awarded by the European Patent Office (EPO) in 2021.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
